Porto, Portugal – July 9th, 2019: IncBio, a leading Portuguese engineering company specializing in the design and construction of cutting-edge biorefinery plants, has signed a contract with Endopure, a company owned by 1Pure, based in California, USA, with operations also in Brazil. This exciting new project will see the development of Portugal’s first CBD and THC extraction plant, designed to transform dry cannabinoid flowers into pharmaceutical-grade cannabinoid API concentrates.
This new facility marks a significant milestone for Endopure, as it will be their first production plant. Currently, the company relies on subcontracting for its cannabinoid products, but with the construction of this plant, Endopure will take a major step toward expanding its in-house production capabilities. The plant, designed to meet the highest standards of quality and compliance, will be operational by early 2022.
José Marques, CEO of IncBio, stated: “We are thrilled to partner with Endopure to bring their vision of creating top-tier cannabinoid products to life. Our expertise in advanced bioprocessing technologies, combined with Endopure’s commitment to quality and innovation, will result in a facility capable of producing world-class CBD and THC concentrates.”
This project will solidify Endopure’s position as a key player in the cannabinoid industry, offering natural and highly regulated products to meet growing global demand. The facility will adhere to cGMP standards and ensure compliance with pharmaceutical-grade quality control, aligning with 1Pure’s mission to provide superior cannabinoid products that are both natural and cost-effective.